研究亮點

　　本中心的研究領域包括分子細胞信號傳遞機轉、基因及表觀基因調控、能量代謝、以及聚焦於腫瘤免疫微環境的研究等，目標是達到早期發現，預防控制，逐步發展出創新且有效的治療策略，並藉由本校強大的臨床資源，針對高挑戰性的困難癌症如三陰性乳癌、肝癌、胰臟癌、腦癌、肺癌、頭頸癌及大腸直腸癌，積極推動臨床試驗、專利及技轉，將生醫產業導入本中心的研究遠景。

　　近期本校洪校長團隊所發現之去除醣基的分子技術，能夠精準檢測腫瘤之PD-L1蛋白，有效提升癌症病人對免疫療法的成功率。另一方面，針對細胞外泌體的研究，讓我們了解到癌細胞如何經由遠距離投射系統傳遞抗藥功能及遠方轉移，進而於肺癌抗藥性的議題做出重大發現，根據上述堅實的研究基礎，提出新穎的合併治療策略。此外，洪校長團隊透過國際合作發現肝癌治療新標靶，該成果發表於近期頂尖國際期刊“自然”《Nature》，在精準醫療研究史上寫下嶄新的一頁。

摘要圖檔	標題/期刊	作者-中心參與人員
	The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis.  Nature, 580:530-535, 2020 Apr.	洪明奇
	PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy.  Journal of Hepatology, 77(1):140-151, 2022 Jul.	洪明奇
	Ribonuclease 7-driven activation of ROS1 is a new potential therapeutic target in hepatocellular carcinoma.  Journal of Hepatology, 74(4):907-918, 2021 Apr	許榮茂 王紹椿 洪明奇
	PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nature Cell Biology, 22(10):1264-1275, 2020 Oct.	許榮茂 洪明奇
	Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nature Cancer, 3(10):1211-1227, 2022 Oct.	張為超 山口浩史 王紹椿 洪明奇
	TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. Journal of Clinical Investigation, 131(8):e139434, 2021 Apr.	山口浩史 許榮茂 洪明奇
	Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases. Science Translational Medicine, 12(545):eaaz5387, 2020 May.	張為超 洪明奇
	LipidSig: a web-based tool for lipidomic data analysis.  Nucleic Acids Research, 49(W1):W336-W345, 2021 Jul.	鄭維中
	Three-dimensional two-color dual-particle tracking microscope for monitoring DNA conformational changes and nanoparticle landings on live cells. ACS Nano, 14(7):7927-7939, 2020 Jul.	劉彥良
	Stem cell–nanomedicine system as a theranostic bio-gadolinium agent for targeted neutron capture cancer therapy. Nature Communications, 14(1):285, 2023 Jan.	鄭隆賓 江智聖
	MRNIP condensates promote DNA double-strand break sensing and end resection.  Nature Communications, 13(1):2638, 2022, May.	洪明奇
	Glucocorticoid receptor regulates PD-L1 and MHCI in pancreatic cancer cells to promote immune evasion and immunotherapy resistance.  Nature Communications, 12:7014, 2021 Dec.	洪明奇
	Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nature Communications, 12(1):2788, 2021 May.	楊文豪 王紹椿 山口浩史 洪明奇
	Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy.  Nature Communications, 12:832, 2021 Feb.	張為超 許榮茂 洪明奇
	Structure and non-canonical Cdk8 activation mechanism within an Argonaute-containing Mediator kinase module.  Science Advances, 7(3):eabd4484, 2021 Jan.	李易撰
	Phosphorylation and stabilization of PD-L1 by CK2 suppresses dendritic cell function.  Cancer Research, 82(11):2185-2195, 2022 Jun.	許榮茂 張為超 洪明奇
	Homogeneous antibody and CAR-T cell with improved effector functions targeting SSEA-4 glycan on pancreatic cancer.  Proceedings of the National Academy of Sciences of the United States of America, 118 (50):e2114774118, 2021 Dec.	林志偉
	Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.  Journal for ImmunoTherapy of Cancer, 9(10):e003050, 2021 Oct.	邱紹智
	Identification of theranostic factors for patients developing metastasis after surgery for early-stage lung adenocarcinoma. Theranostics, 11(8):3661-3675, 2021 Jan.	鄭維中 黃智洋 趙坤山 佘玉萍
	ERα determines the chemoresistant function of mutant p53 involving the switch between lincRNA-p21 and DDB2 expressions. Molecular Therapy-Nucleic Acids, 25:536-553, 2021 Aug.	鄭維中 劉良智 黃偉謙